Edition:
United Kingdom

Caladrius Biosciences Inc (CLBS.OQ)

CLBS.OQ on NASDAQ Stock Exchange Capital Market

2.47USD
13 Sep 2019
Change (% chg)

$0.01 (+0.41%)
Prev Close
$2.46
Open
$2.45
Day's High
$2.58
Day's Low
$2.43
Volume
2,599
Avg. Vol
5,780
52-wk High
$6.83
52-wk Low
$2.18

Latest Key Developments (Source: Significant Developments)

Caladrius Biosciences Reports Q2 Loss Per Share $0.49
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS 2019 SECOND QUARTER AND FIRST SIX MONTHS FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.49.AS OF JUNE 30, 2019, CALADRIUS HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $33.7 MILLION.  Full Article

Caladrius Biosciences Reports Q3 Loss Per Share Of $0.36 From Continuing Operations
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.36 FROM CONTINUING OPERATIONS.CALADRIUS BIOSCIENCES - AS OF SEPT 30 CO HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $46.1 MILLION VERSUS $60.1 MILLION AS OF DEC 31, 2017.CALADRIUS BIOSCIENCES - EXPECTS CASH BALANCE WILL ALLOW CO TO FUND CURRENT BUSINESS PLAN BEYOND 2019.  Full Article

Caladrius Biosciences Reports Q1 Loss Per Share $0.52 From Continuing Operations
Thursday, 10 May 2018 

May 10 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.52 FROM CONTINUING OPERATIONS.  Full Article

Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops
Thursday, 22 Mar 2018 

March 22 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.40 FROM CONTINUING OPERATIONS.CALADRIUS - ‍AS OF DEC 31, 2017, CO HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE SECURITIES OF $60.1 MILLION VERSUS $7.1 MILLION AS OF DEC 31, 2016​.CALADRIUS BIOSCIENCES - ‍CONFIDENT THAT CASH BALANCES, ADDITIONAL GRANT FUNDING WILL ALLOW IT TO FUND ITS CURRENT BUSINESS PLAN BEYOND 2019​.  Full Article

Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA.CALADRIUS BIOSCIENCES INC - UNDER DEAL TERMS , ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS TO DATA SET, REGULATORY FILINGS FOR CD34+ CELL THERAPY PROGRAM.CALADRIUS BIOSCIENCES INC - IN EXCHANGE, SHIRE WILL RECEIVE UNDISCLOSED UP-FRONT CONSIDERATION, MILESTONES AND A ROYALTY ON PRODUCT SALES.CALADRIUS BIOSCIENCES INC - ACQUIRED FROM SHIRE PLC AN EXCLUSIVE WORLDWIDE LICENSE TO DATA FROM A LATE STAGE CD34+ CELL THERAPY PROGRAM.  Full Article

Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES INC - ENTERED INTO A COMMON STOCK SALES AGREEMENT WITH H.C. WAINWRIGHT & CO HAVING AGGREGATE OFFERING PRICE OF UP TO $12 MILLION.  Full Article

Caladrius Biosciences reports 2017 third quarter results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Caladrius Biosciences Inc :Caladrius Biosciences reports 2017 third quarter results.Q3 loss per share $0.38 from continuing operations.  Full Article